Item 1.02 Termination of a Material Definitive Agreement.
On January 13, 2020, Haemonetics Corporation (the "Company"), Cora Healthcare,
Inc. and CoraMed Technologies, LLC (together with Cora Healthcare, Inc., the
"Cora Parties") terminated that certain Second Amended and Restated License
Agreement No. 3 dated as of August 14, 2013 (the "License Agreement") in
connection with the parties' simultaneous entry into a definitive agreement (the
"Agreement") pursuant to which the Company acquired the intellectual property
assets underlying its TEG® 6S Hemostasis Analyzer System (the "Acquired Assets")
from the Cora Parties. The Company previously licensed the Acquired Assets from
the Cora Parties under the terms of the License Agreement, which granted the
Company exclusive, perpetual rights to manufacture and commercialize the TEG 6S
system in the field of hospitals and hospital laboratories in exchange for
certain ongoing payment obligations to the Cora Parties.
Item 7.01 Regulation FD Disclosure.
On January 14, 2020, the Company issued a press release announcing its purchase
of the Acquired Assets from the Cora Parties pursuant to the Agreement. A copy
of the press release is attached as Exhibit 99.1 hereto and is incorporated into
this Item 7.01 by reference.
The information furnished in this Item 7.01 shall not be deemed to be "filed"
for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the "Exchange Act"), or otherwise subject to the liability of such section, nor
shall such information be deemed to be incorporated by reference in any filing
under the Securities Act of 1933, as amended, or the Exchange Act, regardless of
the general incorporation language of such filing, except as shall be expressly
set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. Description
99.1 Press release dated January 14, 2020--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
HAEMONETICS CORPORATION 
